<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035538</url>
  </required_header>
  <id_info>
    <org_study_id>A94_01BE1909</org_study_id>
    <nct_id>NCT04035538</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Replicate-crossover Study to Compare the Safety and Pharmacokinetics of CKD-320 and D012 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to compare the safety and pharmacokinetics of CKD-320 and D012
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, single-dose, replicate-crossover study to compare the safety and
      pharmacokinetics of CKD-320 and D012 in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-320</measure>
    <time_frame>predose(0 hour), 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-320</measure>
    <time_frame>predose(0 hour), 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-320</measure>
    <time_frame>predose(0 hour), 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of CKD-320</measure>
    <time_frame>predose(0 hour), 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CKD-320</measure>
    <time_frame>predose(0 hour), 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf of CKD-320</measure>
    <time_frame>predose(0 hour), 0.17, 0.33, 0.67, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-320, D012</intervention_name>
    <description>R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO</description>
    <arm_group_label>A group</arm_group_label>
    <arm_group_label>B group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult older than 19 years at the time of screening

          2. Body weight more than 55kg and within ±20% of the calculated ideal body weight(IBW =
             (height -100) x 0.9)

          3. No congenital or chronic disease and no pathological symptoms or findings

          4. Suitable subject who is determined to be suitable in laboratory testing such as
             hematology, blood chemistry, urinalysis and 12-lead electrocardiogram

          5. Subject who have received a detailed explanation of this clinical trial and have fully
             understood it, and agree in writing to comply

        Exclusion Criteria:

          1. Subject who has a history of clinical significant hepatobiliary, kidney, digestive,
             respiratory, blood-oncology, endocrine, urinary, psychiatric, musculoskeletal, immune,
             acute and unstable heart failure or evidence

          2. Subject with a history of gastrointestinal disorders(Crohn's disease, ulcer, acute or
             chronic pancreatitis) or gastrointestinal surgery(except for simple appendicitis
             surgery or hernia surgery) that may affect the absorption

          3. A hereditary angioedema patient, with a history angioedema, or hereditary fructose
             patient

          4. Clinical laboratory test results showing the following values

               -  ALT or AST &gt; 2 times upper limit of normal range

               -  eGFR &lt; 60mL/min/1.73m2

          5. Subject with a history of overreaction or clinical significant hypersensitivity to
             drugs

          6. Subject who has a systolic blood pressure &gt; 140mmHg or &lt; 100mmHg, diastolic blood
             pressure &gt; 90mmHg or &lt; 60mmHg, pulses ≥ 100 per minutes

          7. In case of past history of drug abuse or positive for urine test of drug abuse

          8. Those taking medication known to significantly induce or inhibit drug metabolizing
             enzymes within 30days before the first administration of clinical trial drug

          9. Those taking prescription drugs, natural drug(ex, St. John's wort), herbal medicine
             within 14days and non-prescription drugs or vitamin supplements within 7days before
             the first administration of clinical trial drug

         10. Those taking other clinical trial drugs or bioequivalence test drugs within 6months
             before the first administration of clinical trial drug

         11. Those who donated whole blood within 2 months or those who donated the components
             within 1 month or blood transfusion within 1 month before the first administration of
             the clinical trial drug

         12. Subject who has a history of regular alcohol consumption exceeding 210g/week within
             6months of screening (1 glass of beer(5%)=10g, 1 glass of soju(20%)=8g, 1 glass of
             wine(12%)=12g)

         13. &gt; 10 smokers per day within 3months of screening and those who can't quit smoking

         14. Blood test(RPR Ab, HBS Ag, HCV Ab, anti HIV(AIDS)) results indicate a positive

         15. Subject who can't comply with the lifestyle guidelines

         16. A pregnant(a likely), breastfeeding women

         17. Subject who don't agree or can't comply reliable contraception from screening to
             14days after the last drug administration

         18. Subject who is judged by the investigator principal to be ineligible to participate in
             the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jang-Hee Hong</last_name>
    <phone>+82-42-280-6940</phone>
    <email>boniii@cnu.ac.kr</email>
  </overall_contact>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CKD-320</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

